MedTrace Logo

Phase I Trial of Docetaxel and Low-Dose Fractionated Radiation in the Treatment of Metastatic or Recurrent NSCLC

NCT00378404 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2015-06-08

No results posted yet for this study

Summary

The purpose of this study is to assess the maximum tolerated dose of low-dose radiation in combination with Docetaxel in recurrent or metastatic non-small cell lung cancer for second-line therapy.

Conditions

Interventions

DRUG

Docetaxel

30 mg/m2 IV on days 1, 8, 15 every 28 days for 6 cycles

RADIATION

Radiation

50 - 80 cGy on days 1, 8, 15 every 28 days for 6 cycles

Sponsors & Collaborators

  • Kentucky Lung Cancer Research Program

    collaborator OTHER

  • Susanne Arnold

    lead OTHER

Principal Investigators

  • Susanne Arnold, MD · University of Kentucky

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-11-30
Primary Completion
2009-06-30
Completion
2010-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00378404 on ClinicalTrials.gov